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Abstract
Background: Nationwide epidemiologic data on rhinitis in the elderly do not
exist. This study aimed to estimate the prevalence of rhinitis in the population
aged 65 years or above in mainland Portugal and to characterize and classify
rhinitis in this age group.
Methods: Cross-sectional, nationwide, population-based survey of citizens aged
65 years or above, living in mainland Portugal. Current rhinitis (CR) was defined
as the presence of at least two symptoms: ‘repeated sneezing and itchy nose’,
‘blocked nose for more than one whole hour’, or ‘runny nose when not having a
cold or flu’, either usually or in the last 12 months.
Rhinitis severity was assessed using a visual analogue scale; rhinitis was classi-
fied according to ARIA.
Results: Data were obtained from 3678 responders (92.5% response rate). The
prevalence of CR was 29.8% (95% confidence interval (CI): 28.4%–31.3%):
49.1% had mild intermittent, 7.0% mild persistent, 27.5% moderate-severe inter-
mittent, and 16.4% moderate-severe persistent rhinitis. Only 38.6% of patients
with CR had been physician diagnosed and 38.7% were under treatment for this
disease in the previous year. Allergic conjunctivitis symptoms were referred by
68.6% of subjects with CR (rhinoconjunctivitis population prevalence, 20.5%
(95% CI: 19.2%–21.8%)).
Conclusions: Rhinitis and rhinoconjunctivitis are common but underdiagnosed and
undertreated diseases in the geriatric population. This was the first nationwide
epidemiological survey classifying rhinitis according to ARIA guidelines in this age
group. More than 40% of old-age patients presented moderate-severe disease.
Allergic rhinitis is a common chronic respiratory disease,
with a reported prevalence of up to 40% in children and
30% in adults (1–3). It is frequently associated with allergic
conjunctivitis, asthma, and other comorbidities. Considering
its high impact on patient’s quality of life and economic bur-
den (4, 5), allergic rhinitis is regarded as a global public
health problem.
In the last decades, the increase in elderly population has
been noteworthy in industrialized countries. The increase in
life expectancy goes in parallel with a concern for better
quality of life. Studies on allergic and respiratory diseases in
geriatric populations have shown that allergens, infections,
and irritants can be important triggers of inflammation,
regardless of age-related physiologic changes in the immune
system, connective tissue, and vasculature that may predis-
pose for chronic rhinitis (6–10).
Whereas rhinitis was considered to be highly prevalent in
children and young adults, epidemiologic studies suggest that
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it is common in older subjects (11). However, epidemiologic
data on rhinitis in the elderly are scarce (12, 13). Studies spe-
cifically addressing this age group are needed for a proper
analysis of rhinitis in geriatrics, allowing better knowledge
and raised awareness concerning this disease in the growing
elderly population.
This study aimed to estimate the prevalence of rhinitis in
the population aged 65 years or above in mainland Portugal
and to classify its severity according to ARIA. Secondary
aims were to characterize rhinitis symptoms, associated
conjunctivitis, and asthma, and to describe the frequency of
physician diagnosis and rhinitis medication use.
Methods
Study design and participants
Population-based, cross-sectional survey applied by face-
to-face interview to citizens aged 65 years or above, living in
mainland Portugal.
A stratified (by gender, age, and region), multistep defined
sample was used. In a first phase, the number of needed par-
ticipants from each Portuguese region was defined. This esti-
mation was based on the data from the 2001 Portuguese
Census on individuals aged 65 years or above (14) and took
into account the second level of the Portuguese Nomencla-
ture of Territorial Units for Statistics (NUTS II), which
divides mainland Portugal in five regions: North, Centre,
Lisbon and Tagus Valley, Alentejo, and Algarve (Figure S1
represents the distribution of the included elders in each
region across mainland Portugal). In a second phase, munici-
palities were selected within each of the five Portuguese
regions until reaching a prespecified number of elder subjects
in proportion to the sample size. The selection criteria of
municipalities correspond to the aging index, population den-
sity, and purchasing power, indicators that summarize the
main regional social disparities (14). The distribution by
municipalities was based on the levels of differentiation in
each region against the factors used to stratify the sample.
Population density and purchasing power levels were defined
considering the median (national) and standard deviation.
The final selection was made using a random-route method-
ology, where households and nursing homes were included,
in each location. (Table S1 shows the comparison between
the Portuguese population aged 65 years or above, the pre-
dicted sample, and the true sample, considering age, gender,
and region).
Informed consent was obtained from all participants. This
study’s protocol was reviewed and approved by the Ethics
Committee of the Hospital CUF-Descobertas, Lisbon, Portugal.
Instruments and data collection
The instrument for data collection (Table S2) was adapted
from the questionnaire used in our previous study (3). A few
questions were added regarding age of onset of rhinitis
symptoms, physician-diagnosed asthma, and use of medica-
tion for asthma treatment. The questionnaire included items
previously used in the European Community Respiratory
Health Survey (15) (ECRHS) and was adapted to old-age
subjects.
Rhinitis severity was assessed using a 0–10 visual analogue
scale (VAS), as previously suggested (16).
Questionnaires were applied by trained interviewers
between May and July 2008.
Definitions
Definitions used in this study are presented in Table 1. In
individuals with rhinitis, it was further classified into inter-
mittent/persistent and mild/moderate-severe, according to
current ARIA guidelines (4) (Table 1).
Sample size and statistical analysis
To estimate the prevalence of rhinitis in the elderly Portu-
guese population, with an expected national prevalence of
25% and considering an error margin of 1.5% and a confi-
dence interval of 95%, we would need a sample including
3500 subjects. A nonresponse rate of 12.5% was assumed.
Therefore, 4000 subjects were invited to participate.
Categorical variables were described using absolute and
relative frequencies with 95% confidence intervals (95% CI);
comparisons were performed using the Pearson’s chi-squared
test.
Continuous variables were described with mean and stan-
dard deviation (SD); for comparisons, an independent sam-
ples t-test was used.
A significance level of 5% was considered.
Multiple logistic regression analysis was used to calculate
odds ratios (ORs) with 95% CI separately for current
rhinitis, physician-diagnosed rhinitis, and rhinoconjunctivitis
(detailed in Table S3).
Data analyses were performed using SPSS version 17.0
for Windows (IBM SPSS, Chicago, IL, USA).
Results
Participants
A total of 3699 of 4000 invited subjects answered the ques-
tionnaire (response rate 92.5%). There was no evidence of
different response rates according to age. From the answered
questionnaires, 21 were excluded: 13 subjects were aged
<65 years and eight had insufficient information due to
incomplete interviews. A total of 3678 individuals were
included in the analysis (Table S4 – shows the missing data
regarding each variable). Participants’ socio-demographic
characteristics are summarized in Table 2.
Prevalence of current rhinitis, physician-diagnosed rhinitis,
and rhinoconjunctivitis
The prevalence of current rhinitis was 29.8% (95% CI:
28.4%–31.3%). Current rhinitis prevalence was similar in
men and women as well as in age groups, and no differences
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were observed between urban and rural municipalities
(Table 3). In two Portuguese regions, current rhinitis preva-
lence was higher than the national prevalence (P < 0.0001):
Alentejo (57.7%) and Lisbon and Tagus Valley (35.7%). In
the Algarve (8.4%) and Centre (14.6%), current rhinitis prev-
alence was significantly lower than the national prevalence
(P < 0.001). Adjusting for independent variables in Table S3,
living in Alentejo yielded a high OR, 3.19 (95% CI: 2.45–
4.17), for current rhinitis, while living in Lisbon and Tagus
Valley region was a weak but statistically significant risk for
current rhinitis (OR 1.29; 95% CI: 1.08–1.52). Living in the
Centre or in the Algarve was a protective factor for current
rhinitis (Table S3).
Physician-diagnosed rhinitis was reported by 38.6% sub-
jects with current rhinitis (population prevalence 13.1%, 95%
CI: 12.0%–14.2%) and 38.7% had been under treatment for
this disease in the previous year. The frequency of current
rhinitis among those with physician-diagnosed rhinitis was
87.9%. The prevalence of physician-diagnosed rhinitis was
lower than that of current rhinitis in all Portuguese regions
(Table 3). This difference was greater in Alentejo, a region
associated with a high risk of current rhinitis, but a low risk
for physician-diagnosed rhinitis (Table S3).
Symptoms of allergic conjunctivitis were reported by
68.6% of subjects with current rhinitis, accounting for a
prevalence of rhinoconjunctivitis of 20.5% (95% CI: 19.2%–
21.8%) in the studied population (Table 3). The risk of
rhinoconjunctivitis was dependent on the Portuguese region.
Living in a nursing home was significantly associated with
current rhinitis, physician-diagnosed rhinitis, and rhinocon-
junctivitis (Table S3).
Elders with physician-diagnosed asthma or currently on
treatment for asthma presented significantly higher preva-
lence of current rhinitis, physician-diagnosed rhinitis, and
rhinoconjunctivitis (Table 3). In univariate analysis, having
physician-diagnosed asthma was strongly associated with all
three conditions, in particular with current rhinitis and rhino-
conjunctivitis (Table S3).
Table 2 Socio-demographic characteristics of the participants
(n = 3678)
n (%)
Gender
Female 2151 (58.5)
Age, years
65–74 2128 (57.9)
75–84 1204 (32.7)
≥85 346 (9.4)
Residency
Own house 2657 (73.2)
Relatives 632 (17.4)
Nursing home 343 (9.4)
Municipality
Urban 2752 (76.5)
Rural 845 (23.5)
Portuguese Region
North 1168 (31.8)
Centre 789 (21.5)
Lisbon and Tagus Valley 1271 (34.6)
Alentejo 284 (7.7)
Algarve 166 (4.5)
Table 1 Definitions used in this study
Variable Source Definition
Current rhinitis Based on ECRHS and
ARIA (3, 4,15)
Presence, usually or in the last 12 months, of at least two of the
following symptoms: ‘repeated sneezing and itchy nose’; ‘blocked
nose for more than one whole hour’; or ‘runny nose when not
having a cold or flu’
Intermittent rhinitis Built according to ARIA (4) Current rhinitis with nasal symptoms lasting <4 days in a week or
lasting more than 4 days/week, but <4 consecutive weeks
Persistent rhinitis Built according to ARIA (4) Current rhinitis with nasal symptoms lasting for at least 4 days in a
week and for more than 4 consecutive weeks
Mild rhinitis Adapted from Bousquet et al. (16) Current rhinitis that had a visual analogue scale severity score ranging
between 0 and 5
Moderate-severe rhinitis Adapted from Bousquet et al. (16) Current rhinitis that had a visual analogue scale severity score ranging
between 6 and 10
Rhinoconjunctivitis Adapted from ECRHS (15) Presence of rhinitis and a positive answer to the question ‘Do nasal
symptoms usually occur along with red or itchy–watery eyes?’
Physician-diagnosed rhinitis Additional question (3) Positive answer to the question ‘Has a doctor ever said you have
rhinitis?’
Previous performed skin
prick tests
Additional question (3) Positive answer to the question ‘Has a doctor ever asked you to
make skin prick tests?’
Physician-diagnosed asthma Adapted from ECRHS (15) Positive answer to the question ‘Has a doctor ever said you have
asthma?’
Current treatment for rhinitis Adapted from ECRHS (15) Positive answer to the question ‘Have you had any medication for
rhinitis (nasal topical drug or pill) in the last 12 months?’
Current treatment for asthma Adapted from ECRHS (15) Positive answer to the question ‘Do you take medication for asthma?’
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Rhinitis characterization and classification
Among participants classified as having current rhinitis, the
most commonly reported symptom was ‘runny nose when
not having a cold or flu’ (31.1%), followed by ‘repeated
sneezing and itchy nose’ (30.0%; Fig. 1); 22.5% reported to
have all the questioned symptoms either usually or in the last
12 months.
In 39.0% of these individuals, rhinitis symptoms had
started between 20 and 40 years of age; 19.6% reported that
rhinitis symptoms started before the age of 20, 16.5%
between 40 and 60 years, and 4.6% after the age of 60
(20.3% did not know/did not answer). The overall symptom
duration was of more than 25 years in 60.1% of the elders.
There were no significant gender differences in the age of
onset of rhinitis symptoms.
Nasal symptoms were present for more than 4 days per
week in 42.8% of cases and more than 4 weeks in a year in
50.8%. The mean (SD) value for rhinitis severity, considering
the 0–10 VAS, was 4.9(2.3). The overall VAS results are
presented in Fig. 2.
Rhinitis was classified as mild intermittent in 49.1% of all
cases, moderate-severe intermittent in 27.5%, mild persistent
in 7.0%, and moderate-severe persistent in 16.4%. The prev-
alence of each rhinitis type and its characterization are
expressed in Table 4. Elderly subjects living in urban regions
had a higher prevalence of moderate-severe intermittent and
mild persistent rhinitis, while those living in rural regions had
higher frequency of moderate-severe persistent rhinitis
(Table 4). Two Portuguese regions, Alentejo and Lisbon and
Tagus Valley, presented higher prevalence of intermittent
Table 3 Prevalence of current rhinitis, physician-diagnosed rhinitis, and rhinoconjunctivitis (n = 3678)
Current rhinitis Physician-diagnosed rhinitis Rhinoconjunctivitis
% [95% CI] % [95% CI] % [95% CI]
Whole sample 29.8 [28.4–31.3] 13.1 [12.0–14.2] 20.5 [19.2–21.8]
Gender 0.086* 0.052* 0.087*
Male 28.3 [26.0–30.6] 11.8 [10.2–13.4] 19.1 [17.1–20.1]
Female 30.9 [29.0–32.9] 14.0 [12.5–15.5] 21.4 [19.7–23.1]
Age, years 0.667* 0.530* 0.378*
65–74 30.2 [28.3–32.2] 12.6 [11.2–14.0] 20.9 [19.2–22.6]
75–84 28.9 [26.3–31.5] 14.0 [12.0–16.0] 19.3 [17.1–21.5]
≥85 30.9 [26.0–35.8] 13.1 [9.5–16.7] 22.3 [17.9–26.7]
Municipality 0.082* 0.207* 0.419*
Urban 30.7 [29.0–32.4] 13.5 [12.2–14.8] 20.9 [19.4–22.4]
Rural 27.6 [24.6–30.6] 11.9 [9.8–14.0] 19.7 [17.0–22.4]
Region <0.0001* <0.0001* <0.0001*
North 30.0 [27.4–32.6] 16.4 [14.3–18.5] 23.2 [20.8–25.6]
Centre 14.6 [12.1–17.1] 9.5 [7.5–11.6] 8.7 [6.7–10.7]
Lisbon and Tagus Valley 35.7 [33.1–38.3] 15.0 [13.0–17.0] 24.4 [22.0–26.8]
Alentejo 57.7 [52.0–63.5] 5.3 [2.7–7.9] 33.8 [28.3–39.3]
Algarve 8.4 [4.2–12.6] 4.8 [1.5–8.1] 4.2 [1.2–7.3]
Physician-diagnosed asthma <0.0001* <0.0001* <0.0001*
Absent 23.6 [22.2–25.1] 9.7 [8.7–10.7] 14.6 [13.4–15.8]
Present 81.1 [77.3–84.9] 40.9 [36.1–45.7] 68.3 [63.8–72.9]
Current treatment for asthma <0.0001* <0.0001* <0.0001*
Absent 25.7 [24.2–27.2] 12.2 [11.1–13.3] 16.3 [15.1–17.5]
Present 86.6 [82.6–90.6] 39.8 [34.1–45.5] 71.7 [66.4–77.0]
*P-value.
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Figure 1 Prevalence of rhinitis symptoms reported either usually
or in the past 12 months (n = 3678).
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rhinitis, compared with the other regions (57.0% vs 19.6%
and 30.1% vs 18.4%, respectively, P < 0.0001). Those elders
living in the North had higher prevalence of persistent rhini-
tis (11.9% vs 4.5%, P < 0.0001), and elders living in the
Algarve presented lower prevalence of all classes of rhinitis
(Table 4).
Individuals with physician-diagnosed asthma and those on
current treatment for asthma, when compared with those
without, presented higher prevalence of all classes of rhinitis,
including mild intermittent (Table 4).
Physician-diagnosed rhinitis and previously performed skin
prick tests were more frequent in elderly people with moder-
ate-severe rhinitis (57.4% vs 23.6% and 70.2% vs 50.4% in
mild rhinitis, respectively, P < 0.0001) and in those with per-
sistent rhinitis (80.2% vs 25.5% and 75.4% vs 54.1% in inter-
mittent rhinitis, respectively, P < 0.0001). Likewise, rhinitis
treatment in the previous year was more frequent in elderly
people with moderate-severe rhinitis (56.9% vs 24.1% in mild
rhinitis, P < 0.0001) and in those with persistent rhinitis
(80.2% vs 25.8% in intermittent rhinitis, P < 0.0001).
Rhinoconjunctivitis was also more frequent in subjects
with moderate-severe (83.7% vs 57.0% in mild rhinitis,
P < 0.0001) and persistent rhinitis (92.0% vs 61.6% in inter-
mittent rhinitis, P < 0.0001).
Discussion
In the Portuguese population aged 65 years or above, we
found a high prevalence of current rhinitis and of rhinocon-
junctivitis – 29.8% and 20.5%, respectively. Furthermore,
this study showed that these diseases were underdiagnosed
and undertreated in this age group, despite a overall symp-
tom duration of more than 25 years in the majority of sub-
jects and that almost half had moderate-severe disease.
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Figure 2 Distribution of patients according to visual analogue scale
results in each ARIA class.
Table 4 Prevalence of rhinitis according to classification categories (n = 3678)
Mild intermittent Moderate-severe intermittent Mild persistent Moderate-severe persistent
% [95% CI] % [95% CI] % [95% CI] % [95% CI]
Whole sample 14.4 [13.3–15.5] 8.1 [7.2–9.0] 2.0 [1.6–2.5] 4.8 [4.1–5.5]
Gender 0.846* 0.113* 0.788* 0.483*
Male 14.3 [12.5–16.1] 7.2 [5.9–8.5] 2.0 [1.3–2.7] 4.5 [3.5–5.5]
Female 14.5 [13.0–16.0] 8.6 [7.4–9.8] 2.1 [1.5–2.7] 5.0 [4.1–5.9]
Age, years 0.155* 0.041* 0.936* 0.835*
65–74 15.3 [13.8–16.8] 7.7 [6.6–8.8] 2.0 [1.4–2.6] 4.7 [3.8–5.6]
75–84 13.6 [11.7–15.5] 7.7 [6.2–9.2] 2.2 [1.4–3.0] 5.1 [3.9–6.3]
≥85 11.8 [8.4–15.2] 11.6 [8.2–15.0] 2.0 [0.5–3.5] 4.3 [2.2–6.4]
Municipality 0.837* <0.0001* 0.004* <0.0001*
Urban 14.4 [13.1–15.7] 9.4 [8.3–10.5] 2.4 [1.8–3.0] 4.1 [3.4–4.8]
Rural 14.7 [12.3–17.1] 3.9 [2.6–5.2] 0.8 [0.2–1.4] 7.3 [5.6–9.1]
Region <0.0001* <0.0001* 0.017* <0.0001*
North 12.4 [10.5–14.3] 4.6 [3.4–5.8] 3.1 [2.1–4.1] 8.8 [7.2–10.4]
Centre 6.8 [5.0–8.6] 2.2 [1.2–3.2] 2.0 [1.0–3.0] 3.2 [2.0–4.4]
Lisbon and Tagus Valley 17.0 [14.9–19.1] 13.1 [11.3–15.0] 1.6 [0.9–2.3] 3.8 [2.8–4.9]
Alentejo 37.7 [32.1–43.3] 19.4 [14.8–24.0] 0.7 [0.1–2.5] 0.0 [0.0–1.1]
Algarve 4.8 [1.6–8.1] 1.8 [0.7–3.7] 0.6 [0.0–3.3] 0.0 [0.0–1.8]
Physician-diagnosed asthma <0.0001* <0.0001* <0.0001* <0.0001*
Absent 12.9 [11.8–14.1] 6.3 [5.5–7.1] 1.5 [1.1–1.9] 2.4 [1.9–2.9]
Present 26.7 [22.4–31.0] 22.7 [18.6–26.8] 6.2 [3.8–8.6] 24.2 [20.0–28.4]
Current treatment for asthma <0.0001* <0.0001* <0.0001* <0.0001*
Absent 13.6 [12.5–14.8] 6.7 [5.9–7.5] 1.7 [1.3–2.1] 3.3 [2.7–3.9]
Present 24.7 [19.6–29.8] 24.7 [19.6–29.8] 6.5 [3.6–9.4] 23.7 [18.7–28.7]
*P-value.
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The frequency of rhinitis in the elderly has been addressed
in very few elderly-targeted studies. Ventura et al. (17) found
that rhinitis was present in 16.8% of the patients aged over
65 years referred to an allergology unit. Population-based
studies are even scarcer. Only one study performed in Mexico
City has shown that allergic rhinitis was present in 3.6% of
333 elderly subjects who were attending a social security
recreative center (12). In general epidemiologic studies, sub-
group analysis reported rhinitis prevalence between 16.1%
and 25.9% in the elderly (3, 18–20). However, different
selection criteria and rhinitis definitions restrict interstudy
comparisons.
Although limited by the lack of physician diagnosis confir-
mation, our study is truly population based, nationwide, and
targeted to this specific age group. The sampling strategy
allowed that the number of individuals of each gender, age,
and Portuguese region is reliably correspondent to the struc-
ture of the resident population in mainland Portugal (aged
65 years or above), according to the data from the 2001
National Census (14). Moreover, this is the first large popula-
tion-based study reporting rhinitis classification according to
ARIA guidelines in this age group.
The definition of current rhinitis used in the present
study, combining at least two nasal symptoms, is sugges-
tive of allergic rhinitis (4). This was further reinforced as
there were associated symptoms of red, itchy eyes and tear-
ing (4), reported by the majority of our cases. However,
nonallergic conditions may cause similar symptoms, such
as irritants, atrophic, drug-induced, or infectious rhinitis
(4). Therefore, allergic rhinitis was not defined, as this was
only a questionnaire-based survey, not including any dem-
onstration of specific immunopathologic mechanisms. Still,
this definition of rhinitis was important to exclude some of
other causes, such as the so-called rhinitis of the elderly,
characterized by clear rhinorrhea without other nasal
symptoms (4).
Our present findings are in agreement with our previous
study reporting rhinitis prevalence in adults in Portugal (3).
That study, using questions and a rhinitis definition that were
similar to those used in the present report, found high rhini-
tis prevalence in adults aged 16–95 years (26.1%). In the
same study (3), a subpopulation analysis found that rhinitis
prevalence in subjects aged above 65 years was 25.9%. The
higher prevalence observed in the present study (29.8%) may
reflect either a more accurate estimation of rhinitis in the
elderly or an actual increasing tendency in rhinitis prevalence
in this age group over the last years. A recent nationwide
epidemiologic study performed in 2010 in Portugal, including
individuals from all age groups and reporting rhinitis preva-
lence as a secondary aim, found that 22.1% of included
subjects had rhinitis (21). However, direct comparisons are
limited because different sampling and definitions for rhinitis
were used.
Furthermore, we found a higher prevalence of rhinocon-
junctivitis than that previously reported in adults (18.4%)
(3); this finding is in agreement with a recent study, suggest-
ing that elderly patients have rhinitis plus conjunctivitis more
frequently than young adults (22).
The most common nasal symptom in elders with current
rhinitis was watery rhinorrhea, which differs from studies in
allergic rhinitis in adults (3), where sneezing and itchy nose
were the most reported symptoms. This may be due to con-
comitant age-related changes in nasal physiology in the
elderly (nasal glandular atrophy, vascular changes, decreased
nasal humidification, decreased mucociliary clearance, and
structural changes of the nose) (7, 8, 10, 23), which may con-
tribute to more frequent rhinorrhea. In fact, it is likely that
several mechanisms underlie the pathogenesis of rhinitis in
the elderly, with potential interaction between inflammatory
conditions and the influence of aging on nasal physiology
(24).
As defined by ARIA, we found that 49.1% of the elders
had mild intermittent rhinitis, 7.0% mild persistent rhinitis,
27.5% moderate-severe intermittent rhinitis, and 16.4% mod-
erate-severe persistent rhinitis. Cross-sectional and longitudi-
nal studies have shown that rhinitis symptoms become milder
with age (24–26). However, in this study, more than 40% of
the elders with rhinitis presented moderate-severe disease.
Our data emphasize a significant low prevalence of physi-
cian diagnosis, previous diagnostic skin prick tests, and
treatment for rhinitis. This is especially relevant in the
considerable group of older adults reporting moderate-severe
symptoms who lack physician diagnosis and treatment. It
was interesting to notice that, after adjusting for independent
variables, living in nursing homes was associated with current
rhinitis, rhinoconjunctivitis, and also with physician-diag-
nosed rhinitis. Despite more symptomatic, living in a nursing
home may foster better access to health care.
We also found regional differences across mainland Portu-
gal. Living in Alentejo or in Lisbon and Tagus Valley region
was a significant risk of current rhinitis. The greater differ-
ence between current rhinitis and physician-diagnosed rhinitis
prevalence was observed in Alentejo. This may be related to
the fact that the vast majority of elders living in this region
had intermittent rhinitis (98.8%), but may also reflect lower
access to health care in this area. Alentejo is an inland
region, also characterized by the highest absolute pollen con-
centrations in mainland Portugal, which occur seasonally,
due fundamentally to the pollination of Poaceae (27). This
may be associated with the high frequency of intermittent
rhinitis we observed in this region.
Although overall rhinitis prevalence did not differ between
elders living in rural or urban regions, those living in a rural
region had a higher prevalence of moderate-severe persistent
rhinitis. This was an unexpected result. Several studies have
found that the prevalence of allergic rhinitis is higher in
urban than in rural areas (28–30). Moreover, in our previous
study in adults (3), rural inhabitants presented significantly
higher levels of intermittent rhinitis. It is possible that con-
founding factors, such as lifetime changes in the living region
(from urban to rural regions and vice versa), may contribute
to these results.
The importance of the underdiagnosis of rhinitis is further
reinforced by the association we observed between all ARIA
classes of rhinitis and asthma in this age group. Current
rhinitis and rhinoconjunctivitis were strongly associated with
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physician-diagnosed asthma. Although only self-reported,
physician-diagnosed asthma was studied, our results support
an extensive nose–lung interaction in older individuals, as
observed by others (9, 31–33). This association may justify
the importance of rhinitis physician diagnosis, including in
milder forms of the disease.
Addressing rhinitis in the geriatric population is recognized
as an important existing unmet need (4), especially consider-
ing the increase in the elderly population throughout Europe
together with the aim to stimulate active, healthy aging. The
present study reveals that rhinitis and rhinoconjunctivitis are
highly prevalent but underdiagnosed and undertreated dis-
eases in the elderly population, despite that over 40% have
moderate-severe disease.
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